Funding (Selection):

CardioReGenix:

Development of Next-Generation Gene Therapies for Cardiovascular Disease

Duration: January 1, 2019 – June 30, 2024


TRAIN-HEART:

RNA therapeutics for heart failure, European training Network

A Marie Sklodowska-Curie Innovative Training Network for 15 PhD fellows

Duration: 2019 – August 2023


SFB1470 HFpEF:

Multilevel mechanistic characterisation of Heart Failure with Preserved Ejection Fraction - Towards a novel classification of HFpEF for targeted therapies.


FIBREX:

Targeting cardiac fibrosis with next generation RNA therapeutics

Duration: August 2022 – May 2024


ERC Advanced Grant REVERSE:

Circular RNAs to reverse pathological remodelling of the injured heart

Duration: October 1, 2022 – September 30, 2027


COFONI:

Untersuchung von zirkulären RNAs als Mediatoren der SARS-CoV-2-Infektion im kardiovaskulären System

Duration: February 2022 – January 2025


TransRegio/SFB 267:

„Non-coding RNA in the cardiovascular system”

Sub-Project B01 "CircRNAs in postnatal heart development and cardiac disease"


INNOVATION:

Investigating long non-coding RNA regulated pathways driving cardiac regeneration

Duration: 2019 – December 2023

 


More:

  • EU projects:

  1. HOMAGE: Heart OMics in AGEing (2013 – 2019)
  2. ERC Consolidator Grant LONGHEART: Exploring selected long non-coding RNAs as diagnostics and therapeutic targets for heart failure (2015 – 2020)
  3. EU funding via N-Bank - im Rahmen des Niedersächsischen Innovationsförderprogramms für Forschung und Entwicklung in Unternehmen: Entwicklung einer Kardiomyozyten-spezifischen CHAST-Therapie zur Behandlung von chronischer Herzschwäche (zusammen mit Cardior Pharmaceuticals GmbH, 2018 – 2021)
  4. ERC Proof-of-Concept Grant MEGFIB: Preclinical development of lncRNA-meg3 inhibitors to treat cardiac fibrosis (2020 – 2021)

 

  • Leducq Foundation:

Trans-Atlantic Network and Training Program on MicroRNA-Based Therapeutic Strategies in Vascular Disease

(MIRVAD, 2014 – 2019)

 

  • DFG:

  1. TH903/18-1 (with ANR): Regulation, diagnostics and therapy focusing on the mineralocorticoid receptor involved in cardiac remodeling (2016 – 2020)
  2. TH903/19-1 (with ANR): CARDINAL - Cardiomyocyte-derived vesicular non coding RNAs and post-ischemic cardiac remodeling (2016 – 2020)
  3. TH903/20-1 (KFO 311): (Prä-)terminales Herz- und Lungenversagen: Mechanische Entlastung und Reparatur, Teilprojekt 9 (2016 – 2019)
  4. TH903/22-1 (FOR 2591): Severity assessment in animal based research (2017 – 2020)
  5. BA5631/2-1: Funktionelle und molekulare Analyse von Telomerase bei der Kardiomyozyten-Proliferation und Herzregeneration (2017 – 2020)
  6. DFG Hoepfner (HO 6855/1-1) - Deciphering the role of miRNAs in Fabry disease pathology and therapy (March 2021 – February 2024)
  7. DFG Jung (JU 3222/2-1) - The molecular role of selected circRNAs in cardiac macrophage dynamics and inflammatory response during cardiac remodeling after myocardial infarction (June 2021 – May 2024)
  8. DFG Bär/Brandenberger (BA 5631/5-1) - “Targeting telomere dysfunction-related immune- and organ senescence in pulmonary and cardiovascular disease” (April 2023 – March 2026)

 

  • European Research Area Network (ERA-Net) projects: 

      ERA-CVD/BMBF, Projektträger DLR

  1. EXPERT: Exploring new pathways in age-related heart diseases (Analyse RNA-basierter Signalwege in altersbedingten Herzerkrankungen; 2017 - 2020) *
  2. LIPCAR: LIPCAR, a prognostic marker of heart failure with reduced ejection fraction (LIPCAR, ein prognostischer Biomarker bei Herzinsuffizienz; 2017 - 2020)

 

  • Else Kröner-Fresenius-Stiftung (EKFS): 

      Else Kröner Medical Scientist Kollegs 2022: nextGENERATION: ReGENERAte Organ FunctION

  1. Natalie Weber; Stammzell-basierte regenerative Therapien kardialer Erkrankungen (July 2023 - July 2026)

 

  • Industry (different projects):

* co-ordinating party

 

  • Further cooperations:

COST CardioRNA